One of the core goals of the Pandemic Agreement is to tackle global disparities in access to vaccines, diagnostics, and treatments. A key part of this effort involves technology transfer—the sharing of know-how, intellectual property, and manufacturing capacity. To that end, the agreement introduces a set of obligations aimed at shifting from a charity-based model to an end-to-end ecosystem grounded in equity. This article examines how effectively the agreement addresses technology transfer—one of the most contested issues in the negotiations.